drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T-cell)
drug_description
Autologous, gene-modified CD19-directed chimeric antigen receptor T-cell therapy administered intravenously; engineered patient T cells express an anti-CD19 CAR to recognize and eliminate CD19+ B cells (naive, memory, plasmablasts), inducing B-cell aplasia and reducing autoreactive B cells and pathogenic autoantibodies in SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express an anti-CD19 chimeric antigen receptor. After infusion, these CAR-T cells bind CD19 on B-lineage cells (naive, memory, plasmablasts) and kill them via T-cell activation and cytolysis, leading to B-cell aplasia and reduction of autoreactive B cells and pathogenic autoantibodies in SLE.
drug_name
IM19 CAR-T cells
nct_id_drug_ref
NCT06513429